Published in J Carcinog on January 17, 2005
Characterisation of Muta™Mouse λgt10-lacZ transgene: evidence for in vivo rearrangements. Mutagenesis (2010) 0.89
Genotoxicity and antigenotoxicity study of aqueous and hydro-methanol extracts of Spondias mombin L., Nymphaea lotus L. and Luffa cylindrical L. using animal bioassays. Interdiscip Toxicol (2015) 0.75
Overall evaluations of carcinogenicity: an updating of IARC Monographs volumes 1 to 42. IARC Monogr Eval Carcinog Risks Hum Suppl (1987) 6.47
Efficient rescue of integrated shuttle vectors from transgenic mice: a model for studying mutations in vivo. Proc Natl Acad Sci U S A (1989) 2.54
Transgenic systems for in vivo mutation analysis. Mutat Res (1993) 2.45
Spectra of spontaneous and mutagen-induced mutations in the lacI gene in transgenic mice. Proc Natl Acad Sci U S A (1991) 2.29
The induction of micronuclei as a measure of genotoxicity. A report of the U.S. Environmental Protection Agency Gene-Tox Program. Mutat Res (1983) 1.90
Distinction of mutagenic carcinogens from a mutagenic noncarcinogen in the big blue transgenic mouse. Environ Health Perspect (1996) 1.40
Analysis of spontaneous and induced mutations in transgenic mice using a lambda ZAP/lacI shuttle vector. Environ Mol Mutagen (1991) 1.32
The in vivo micronucleus assay in mammalian bone marrow and peripheral blood. A report of the U.S. Environmental Protection Agency Gene-Tox Program. Mutat Res (1990) 1.17
A review of the genotoxicity of 1-ethyl-1-nitrosourea. Mutat Res (1993) 1.08
Mutagenicity studies with praziquantel, a new anthelmintic drug, in mammalian systems. Arch Toxicol (1978) 1.07
Temporal and molecular characteristics of mutations induced by ethylnitrosourea in germ cells isolated from seminiferous tubules and in spermatozoa of lacZ transgenic mice. Proc Natl Acad Sci U S A (1995) 1.06
Comparison between in vivo mutagenicity and carcinogenicity in multiple organs by benzo[a]pyrene in the lacZ transgenic mouse (Muta Mouse). Mutat Res (1998) 1.00
Recent advances in the protocols of transgenic mouse mutation assays. Mutat Res (2000) 1.00
Induction of hepatic mutations in lacI transgenic mice. Mutagenesis (1993) 0.99
In vivo transgenic mutation assays. Environ Mol Mutagen (2000) 0.98
In vivo sister chromatid exchange and micronucleus induction studies with 1,3-butadiene in B6C3F1 mice and Sprague-Dawley rats. Mutagenesis (1986) 0.97
Molecular analysis of lacI mutants from bone marrow of B6C3F1 transgenic mice following inhalation exposure to 1,3-butadiene. Carcinogenesis (1994) 0.97
Relative sensitivity of the endogenous hprt gene and lacI transgene in ENU-treated Big Blue B6C3F1 mice. Environ Mol Mutagen (1995) 0.96
Characterization of mutations induced by ethylnitrosourea in seminiferous tubule germ cells of transgenic B6C3F1 mice. Proc Natl Acad Sci U S A (1994) 0.96
Transgenic animal models for detection of in vivo mutations. Annu Rev Pharmacol Toxicol (1995) 0.94
Dose response at low doses of X-irradiation and MMS on the induction of micronuclei in mouse erythroblasts. Mutat Res (1976) 0.90
Comparison of mutant frequencies at the transgenic lambda LacI and cII/cI loci in control and ENU-treated Big Blue mice. Environ Mol Mutagen (1999) 0.88
Target organ and time-course in the mutagenicity of five carcinogens in MutaMouse: a summary report of the second collaborative study of the transgenic mouse mutation assay by JEMS/MMS. Mutat Res (1999) 0.86
Detection of cyclophosphamide-induced mutations at the Hprt but not the lacI locus in splenic lymphocytes of exposed mice. Environ Mol Mutagen (1999) 0.85
A comparative study of in vivo mutation assays: analysis of hprt, lacI, cII/cI and as mutational targets for N-nitroso-N-methylurea and benzo[a]pyrene in Big Blue mice. Mutat Res (1998) 0.85
DNA adducts, mutant frequencies, and mutation spectra in various organs of lambda lacZ mice exposed to ethylating agents. Environ Mol Mutagen (1998) 0.85
Mutations in liver DNA of lacI transgenic mice (Big Blue) following subchronic exposure to 2-acetylaminofluorene. Mutat Res (1993) 0.85
LacI mutation spectra following benzo[a]pyrene treatment of Big Blue mice. Carcinogenesis (2000) 0.85
Comparison of results from mouse bone marrow chromosome aberration and micronucleus tests. Environ Mol Mutagen (1995) 0.84
Mutagenic response of the endogenous hprt gene and lacI transgene in benzo[a]pyrene-treated Big Blue B6C3F1 mice. Environ Mol Mutagen (1996) 0.84
Organ variation in the mutagenicity of dimethylnitrosamine in Big Blue mice. Environ Mol Mutagen (1996) 0.84
Induction of mutations by 2-acetylaminofluorene in lacI transgenic B6C3F1 mouse liver. Mutagenesis (1998) 0.83
Validation studies with Muta Mouse: a transgenic mouse model for detecting mutations in vivo. Environ Mol Mutagen (1991) 0.83
Bioassay of 2,6-Toluenediamine Dihydrochloride for Possible Carcinogenicity (CAS No. 15481-70-6). Natl Toxicol Program Tech Rep Ser (1980) 0.83
Transgenic mice as model systems for studying gene mutations in vivo. Trends Genet (1993) 0.83
Relative activities of methyl methanesulphonate (MMS) as a genotoxin, clastogen and gene mutagen to the liver and bone marrow of MutaMouse mice. Environ Mol Mutagen (1998) 0.82
Evaluation of a three-exposure mouse bone marrow micronucleus protocol: results with 49 chemicals. Environ Mol Mutagen (1993) 0.82
Methyl bromide causes DNA methylation in rats and mice but fails to induce somatic mutations in lambda lacZ transgenic mice. Cancer Lett (1999) 0.82
Micronucleus test and bone-marrow chromosome analysis: a comparison of 2 methods in vivo for evaluating chemically induced chromosomal alterations. Mutat Res (1981) 0.82
Spectrum of mutations in kidney, stomach, and liver from lacI transgenic mice recovered after treatment with tris(2,3-dibromopropyl)phosphate. Environ Mol Mutagen (1996) 0.82
Tissue-specific mutant frequencies and mutational spectra in cyclophosphamide-treated lacI transgenic mice. Environ Mol Mutagen (1999) 0.82
Mutation studies in lacI transgenic mice after exposure to radiation or cyclophosphamide. Mutagenesis (1998) 0.81
The micronucleus test as part of a short-term mutagenicity test program for the prediction of carcinogenicity evaluated by 143 agents tested. Mutat Res (1980) 0.81
Genotoxicity of agaritine in the lacI transgenic mouse mutation assay: evaluation of the health risk of mushroom consumption. Food Chem Toxicol (1995) 0.81
Hepatic lacI and cII mutation in transgenic (lambdaLIZ) rats treated with dimethylnitrosamine. Mutat Res (1998) 0.81
Genetic and related effects: An updating of selected IARC monographs from Volumes 1 to 42. IARC Monogr Eval Carcinog Risks Hum Suppl (1987) 0.81
Species-specific differences in hepatic mutant frequency and mutational spectrum among lambda/lacI transgenic rats and mice following exposure to aflatoxin B1. Carcinogenesis (1996) 0.81
Induction of lacZ mutation by 7,12-dimethylbenz[a]anthracene in various tissues of transgenic mice. Mutat Res (1999) 0.80
Mutagenesis induced by oral carcinogens in lacZ mouse (MutaMouse) tongue and other oral tissues. Carcinogenesis (1999) 0.80
Increased frequency of micronucleated kidney cells in rats exposed to halogenated anaesthetics. Mutat Res (1998) 0.80
Inhaled crocidolite mutagenicity in lung DNA. Environ Health Perspect (2000) 0.80
Subchronic administration of phenobarbital alters the mutation spectrum of lacI in the livers of Big Blue transgenic mice. Mutat Res (2000) 0.80
Effect of ethylnitrosourea and methyl methanesulfonate on mutation frequency in Muta Mouse germ cells (seminiferous tubule cells and epididymis spermatozoa). Mutat Res (1997) 0.80
A comparison of the genotoxicity of ethylnitrosourea and ethyl methanesulfonate in lacZ transgenic mice (Muta Mouse). Mutat Res (1997) 0.80
DNA damage and mutagenesis induced by procarbazine in lambda lacZ transgenic mice: evidence that bone marrow mutations do not arise primarily through miscoding by O6-methylguanine. Carcinogenesis (1997) 0.80
Tamoxifen causes gene mutations in the livers of lambda/lacI transgenic rats. Cancer Res (1997) 0.80
Aflatoxin B1 induced lacI mutation in liver and kidney of transgenic mice C57BL/6N: effect of phorone. Mutagenesis (1996) 0.79
Evidence for in vivo non-mutagenicity of the carcinogen hydrazine sulfate in target tissues of lacZ transgenic mice. Carcinogenesis (1995) 0.79
Response of the Muta mouse lacZ/galE- transgenic mutation assay to DMN: comparisons with the corresponding Big Blue (lacI) responses. Mutat Res (1994) 0.79
Mutations induced in male germ cells after treatment of transgenic mice with ethylnitrosourea. Mutat Res (1997) 0.79
Mutant frequencies and mutation spectra of dimethylnitrosamine (DMN) at the lacI and cII loci in the livers of Big Blue transgenic mice. Mutat Res (2000) 0.79
Multiple organ mutation in the lacZ transgenic mouse (Muta mouse) 6 months after oral treatment (5 days) with benzo[a]pyrene. Mutat Res (1999) 0.79
Evaluation of the in vivo genotoxic potential of three carcinogenic aromatic amines using the Big Blue transgenic mouse mutation assay. Environ Mol Mutagen (1996) 0.79
Detection of chemical mutagens using Muta Mouse: a transgenic mouse model. Mutagenesis (1993) 0.79
NTP Toxicology and Carcinogenesis Studies of o-Phenylphenol (CAS No. 90-43-7) Alone and with 7,12-Dimethylbenz(a)anthracene (CAS No. 57-97-6) in Swiss CD-1 Mice (Dermal Studies). Natl Toxicol Program Tech Rep Ser (1986) 0.78
N-nitroso-n-methylurea. IARC Monogr Eval Carcinog Risk Chem Man (1978) 0.78
Can nongenotoxic carcinogens be detected with the lacI transgenic mouse mutation assay? Environ Mol Mutagen (1993) 0.78
Mutagenicity of o-anisidine to the bladder of lacI- transgenic B6C3F1 mice: absence of 14C or 32P bladder DNA adduction. Carcinogenesis (1994) 0.78
Differential in vivo mutagenicity of the carcinogen/non-carcinogen pair 2,4- and 2,6-diaminotoluene. Carcinogenesis (1995) 0.78
In vivo mutagenicity and DNA adduct levels of heterocyclic amines in Muta mice and c-myc/lacZ double transgenic mice. Mutat Res (1996) 0.78
Assessment of 1,3-butadiene mutagenicity in the bone marrow of B6C3F1 lacI transgenic mice (Big Blue): a review of mutational spectrum and lacI mutant frequency after a 5-day 625 ppm 1,3-butadiene exposure. Environ Mol Mutagen (1996) 0.78
Evaluation of spontaneous and chemical-induced lacI mutations in germ cells from lambda/lacI transgenic mice. Mutat Res (1997) 0.78
Analysis of the mutagenic potential of ENU and MMS in germ cells of male C57BL/6 lacI transgenic mice. Mutat Res (1997) 0.78
The detection of gene mutation in the tubular sperm of Muta Mice following a single intraperitoneal treatment with methyl methanesulphonate or ethylnitrosourea. Mutat Res (1997) 0.78
Assessment of the in vivo mutagenicity of ethylene oxide in the tissues of B6C3F1 lacI transgenic mice following inhalation exposure. Mutat Res (1997) 0.78
Mutagenicity of ethyl carbamate to lacZ- transgenic mice. Mutagenesis (1998) 0.78
Comparison of in vivo mutagenesis in the endogenous Hprt gene and the lacI transgene of Big Blue(R) rats treated with 7, 12-dimethylbenz[a]anthracene. Mutat Res (1998) 0.78
Evidence for the lack of base-change and small-deletion mutation induction by trichloroethylene in lacZ transgenic mice. Environ Mol Mutagen (1999) 0.78
Inhaled benzene increases the frequency and length of lacI deletion mutations in lung tissues of mice. Carcinogenesis (1998) 0.77
Long-term mutagenicity studies with chloroform and dimethylnitrosamine in female lacI transgenic B6C3F1 mice. Environ Mol Mutagen (1998) 0.77
Somatic and germ cell mutagenesis in lambda lacZ transgenic mice treated with acrylamide or ethylnitrosourea. Mutat Res (1997) 0.77
Use of transgenic mutational test systems in risk assessment of carcinogens. Arch Toxicol Suppl (1998) 0.77
The micronucleus test of benzo[a]pyrene with mouse and rat peripheral blood reticulocytes. Mutat Res (1992) 0.77
Effect of mitogenic or regenerative cell proliferation on lacz mutant frequency in the liver of MutaTMMice treated with 5, 9-dimethyldibenzo[c,g]carbazole. Carcinogenesis (1999) 0.77
The detection of gene mutation in transgenic mice (Muta Mouse) following a single oral dose of 2-acetylaminofluorene. Mutagenesis (1995) 0.77
Mutagenicity of the human bladder carcinogen 4-aminobiphenyl to the bladder of MutaMouse transgenic mice. Mutat Res (1998) 0.77
Initial experiences and future directions for transgenic mouse mutation assays. Mutat Res (1994) 0.77
Differential mutagenic activity of IQ (2-amino-3-methylimidazo[4,5-f]quinoline) in Salmonella typhimurium strains in vitro and in vivo, in Drosophila, and in mice. Mutat Res (1985) 0.77
Sodium phenobarbital-enhanced mutation frequency in the liver DNA of lacZ transgenic mice treated with diethylnitrosamine. Mutagenesis (1997) 0.77
The evaluation of sixteen carcinogens in the rat using the micronucleus test. Mutat Res (1978) 0.77
Mutational spectra in the lacl gene in skin from 7,12-dimethylbenz[a]anthracene-treated and untreated transgenic mice. Mol Carcinog (1995) 0.76
Antimutagenic structural modification of quinoline assessed by an in vivo mutagenesis assay using lacZ-transgenic mice. Mutat Res (1998) 0.76
In vivo mutagenicity of ethylene oxide at the hprt locus in T-lymphocytes of B6C3F1 lacI transgenic mice following inhalation exposure. Mutat Res (1997) 0.76
Germ cell mutagenesis in lacZ transgenic mice treated with methyl methanesulfonate. Mutat Res (1997) 0.76
Specific mutational spectrum of dimethylnitrosamine in the lacI transgene of Big Blue C57BL/6 mice. Mutagenesis (1998) 0.76
Mutagenic response to benzene and tris(2,3-dibromopropyl)-phosphate in the lambda lacI transgenic mouse mutation assay: a standardized approach to in vivo mutation analysis. Environ Mol Mutagen (1996) 0.76
Detection of gene mutation in skin, stomach and liver of MutaMouse following oral or topical treatment with N-methyl-N'-nitro-N-nitrosoguanidine or 1-chloromethylpyrene: some preliminary observations. Mutagenesis (1996) 0.76
Mouse lysozyme M gene: isolation, characterization, and expression studies. Proc Natl Acad Sci U S A (1988) 2.84
Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology. Ann Neurol (1997) 1.90
Detection and quantification of latently infected B lymphocytes in Epstein-Barr virus-seropositive, healthy individuals by polymerase chain reaction. J Clin Microbiol (1992) 1.66
Structure-based thresholds of toxicological concern (TTC): guidance for application to substances present at low levels in the diet. Food Chem Toxicol (2004) 1.60
Severe cardiac failure in a patient with multiple sclerosis following low-dose mitoxantrone treatment. Neurology (2009) 1.53
Synergistic immunomodulatory effects of interferon-beta1b and the phosphodiesterase inhibitor pentoxifylline in patients with relapsing-remitting multiple sclerosis. Ann Neurol (1998) 1.40
IPCS conceptual framework for evaluating a mode of action for chemical carcinogenesis. Regul Toxicol Pharmacol (2001) 1.39
Vinyl chloride: still a cause for concern. Environ Health Perspect (2000) 1.37
The detection of human cytomegalovirus immediate early antigen in peripheral blood leucocytes. J Immunol Methods (1991) 1.35
Searching for information on toxicological data of chemical substances in selected bibliographic databases--selection of essential databases for toxicological researches. Chemosphere (1996) 1.18
Gene polymorphism at position -308 of the tumor-necrosis-factor-alpha (TNF-alpha) in multiple sclerosis and it's influence on the regulation of TNF-alpha production. Neurosci Lett (1996) 1.11
Clinical course, pathological correlations, and outcome of biopsy proved inflammatory demyelinating disease. J Neurol Neurosurg Psychiatry (2005) 1.01
Macrophages are eliminated from the injured peripheral nerve via local apoptosis and circulation to regional lymph nodes and the spleen. J Neurosci (2001) 0.98
REPDOSE: A database on repeated dose toxicity studies of commercial chemicals--A multifunctional tool. Regul Toxicol Pharmacol (2006) 0.98
Chlorinated dibenzodioxins and dibenzofurans (PCDD/F) in blood and human milk of non occupationally exposed persons living in the vicinity of a municipal waste incinerator. Chemosphere (1996) 0.98
Identification of glial cell proliferation in early multiple sclerosis lesions. Neuropathol Appl Neurobiol (1998) 0.96
The macrophage activity marker sCD14 is increased in patients with multiple sclerosis and upregulated by interferon beta-1b. J Neuroimmunol (2002) 0.95
Pentoxifylline, a phosphodiesterase inhibitor, induces immune deviation in patients with multiple sclerosis. J Neuroimmunol (1996) 0.91
Effects of low-dose, noncytotoxic, intraarticular liposomal clodronate on development of erosions and proteoglycan loss in established antigen-induced arthritis in rabbits. Arthritis Rheum (2001) 0.86
Assessment of structurally related chemicals: toxicity and ecotoxicity of acrylic acid and acrylic acid alkyl esters (acrylates), methacrylic acid and methacrylic acid alkyl esters (methacrylates). Chemosphere (1995) 0.85
Bcl-2-expressing oligodendrocytes in multiple sclerosis lesions. Glia (1999) 0.81
Evaluation of inhalation TTC values with the database RepDose. Regul Toxicol Pharmacol (2010) 0.81
[Embolic complications in bacterial endocarditis]. Z Kardiol (1997) 0.81
Evaluation of time extrapolation factors based on the database RepDose. Toxicol Lett (2011) 0.78
Mitochondrial permeability transition is altered in early stages of carcinogenesis of 2-acetylaminofluorene. Carcinogenesis (1998) 0.78
Analysis of interleukin-4 receptor alpha chain variants in multiple sclerosis. J Neuroimmunol (2001) 0.78
A longitudinal prospective study of cytomegalovirus pp65 antigenemia in renal transplant recipients. Transpl Int (1993) 0.77
The role of nongenotoxic mechanisms in arylamine carcinogenesis. Environ Health Perspect (1994) 0.77
Dose response for the stimulation of cell division by caffeic acid in forestomach and kidney of the male F344 rat. Fundam Appl Toxicol (1997) 0.77
MxA protein--an interferon beta biomarker in primary progressive multiple sclerosis patients. Eur J Neurol (2008) 0.76
Uptake of persistent environmental chemicals by cultured human cells. Biochem Pharmacol (1987) 0.76
Non-response to maprotiline caused by ultra-rapid metabolism that is different from CYP2D6? Eur J Clin Pharmacol (1997) 0.75
[Reference values for indoor air: dearomatized hydrocarbon solvents (C(9)-C(14))]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz (2005) 0.75
Relevance of non-guideline studies for risk assessment: the coverage model based on most frequent targets in repeated dose toxicity studies. Toxicol Lett (2012) 0.75
Variations in uterine cytosolic oestrogen and progesterone receptor levels during the rat oestrous cycle. Acta Endocrinol (Copenh) (1977) 0.75
Inhalation toxicity of mineral particles: critical appraisal of endpoints and study design. Toxicol Lett (2003) 0.75
Commentary on the application of (Q)SAR to the toxicological evaluation of existing chemicals. Chemosphere (1997) 0.75
Searching for information on chemical substances in selected biomedical bibliographic databases. Chemosphere (1995) 0.75
Early effects in chemical-induced rat liver carcinogenesis: an immunohistochemical study following exposure to 0.04% AAF. Apoptosis (1997) 0.75
[Epidemiologic surveillance of hydatidosis in the Patagonian region, Argentina: 1983-1988]. Bol Chil Parasitol (1991) 0.75
The dual role of 2-acetylaminofluorene in hepatocarcinogenesis: specific targets for initiation and promotion. Mutat Res (1997) 0.75
Improvement of the Cramer classification for oral exposure using the database TTC RepDose--a strategy description. Regul Toxicol Pharmacol (2011) 0.75
Ela 1.0--a framework for life-cycle impact assessment developed by the Fraunhofer-Gesellschaft. Part A: The conceptual framework. Chemosphere (1997) 0.75
Intracellular actions of gonadal steroids. Exp Brain Res (1981) 0.75
Early initiating and promoting effects in 2-AAF-induced rat liver carcinogenesis: an immunohistochemical study. Cancer Lett (1995) 0.75
Interferon-beta1b treatment modulates cytokines in patients with primary progressive multiple sclerosis. Acta Neurol Scand (2006) 0.75